Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, will modify its existing agreement with the U.S. Department of Health and Human Services (HHS), in collaboration with the Department of Defense (DOD), to deliver up to 1.5 million doses of the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373). The agreement will maintain the U.S. public’s access to Novavax’ vaccine and support the developmen...